Patent ID: 11285136

Abstract:
Described herein are loaded nanoparticles of Sorafenib (Sorafenib PBB) or Sorafenib derivatives (Sorafenib PBB derivatives), wherein the nanoparticles are polymeric PBB nanoparticles, (PHEA-BIB-pButMA, α,β-poly(N-2-hydroxyethyl)-co-{N-2-ethylene-[2-(poly(butylmethacrylate)-isobutyrate]}-D, L-aspartamide, as well as a method for obtaining them.Also described herein are a controlled release formulation of Sorafenib or Sorafenib, derivatives that include Sorafenib PBB or Sorafenib PBB derivatives, and to the use of the formulation in the treatment of tumor diseases of the kidney, liver, thyroid, colon, breast, pancreas, lungs and/or recurrent glioblastoma.